Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Артериальная гипертензия у детей и подростков

Список литературы:

  1. Александров А.А., Кисляк О.А., Леонтьева И.В., Розанов В.Б. Диагностика, лечение и профилактика артериальной гипертензии у детей и подростков. Российские рекомендации (второй пересмотр) Кардиоваскулярная терапия и профилактика 2009; 8:(4; приложение 1) 1-32. 4) 1-32.
  2. Александров А.А.., Кисляк О.А., Леонтьева И.В. и др./ Клинические рекомендации Системные гипертензии. 2020; 17:2:7-35|
  3. Чазова И.Е., Жернакова Ю.Е. Клинические рекомендации Диагностика, лечение артериальной гипертензии. Системные гипертензии 2019;16:6-31.
  4. Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 00, 1–98.
  5. Rosenberg WM, Gray JA et al. Evidence based medicine: what it is and what it isn't. BMJ 1996, January; 312 (7023): 71–72.
  6. Андреева Н. С., Реброва О. Ю., Зорин Н. А. и др. Системы оценки достоверности научных доказательств и убедительности рекомендаций: сравнительная характеристика и перспективы унификации. Медицинские технологии. Оценка и выбор. 2012. №. 4. С. 10–24.
  7. Lurbe E., Agabiti-Roseic E., Cruickshankd J.K, Dominiczake A., Erdinef S., Hirthg A., et.al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens. 2016 Oct; 34(10):1887-920. doi: 10.1097/HJH.0000000000001039
  8. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, de Ferranti SD, Dionne JM, Falkner B, Flinn SK, Gidding SS, Goodwin C, Leu MG, Powers ME, Rea C, Samuels J, Simasek M, Thaker VV, Urbina EM. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017; 140(3): e20171904.
  9. Леонтьева И.В., Александров А.А., Розанов В.Б. Артериальная гипертензия у детей и подросков 2010 Москва 246с.
  10. Bochud M, Bovet P, Elston RC, Paccaud F, Falconnet C, Maillard M, et al. High heritability of ambulatory blood pressure in families of East African descent. Hypertension 2005; 45:445–450.
  11. Rosner B, Cook NR, Daniels S, Falkner B. Childhood blood pressure trends and risk factors for high blood pressure: the NHANES experience 1988-2008. Hypertension. 2013; 62(2): 247-54.
  12. Kelishadi R, Mirmoghtadaee P, Najafi H, Keikha M. Systematic review on the association of abdominal obesity in children and adolescents with risk factors. J Res Med Sci. 2015;20(3):294–307
  13. Friedemann C, Heneghan C, Mahtani K, Thompson M, Perera R, Ward AM. Cardiovascular disease risk in healthy children and its association with body mass index: systematic review and meta-analysis. BMJ. 2012;345:e4759
  14. Flechtner-Mors M, Neuhauser H, Reinehr T, Roost HP, Wiegand S, Siegfried W, et al., APV initiative and the BMBF Competence Network Obesity. Blood pressure in 57,915 pediatric patients who are overweight or obese based on five reference systems. Am J Cardiol 2015; 115:1587–1594.
  15. Parker ED,Sinaiko AR, Kharbanda EO, et al. Change in weight status and development of hypertension. Pediatrics. 2016;137(3): e20151662
  16. Koebnick C, Black MH, Wu J, et al. High blood pressure in overweight and obese youth: implications for screening. J Clin Hypertens (Greenwich). 2013;15(11): 793–805
  17. Zhang T, Zhang H, Li S, et al. Impact of adiposity on incident hypertension is modified by insulin resistance in adults: longitudinal observation from the Bogalusa Heart Study. Hypertension. 2016;67(1):56–62
  18. Kaelber DC. IBM explorys cohort discovery tool. Available at: www. ibm. com/ watson/ health/ explorys. Accessed February 3, 2017
  19. Halbach SM, Martz K, Mattoo T, Flynn J. Predictors of blood pressure and its control in pediatric patients receiving dialysis. J Pediatr. 2012;160(4): 621–625
  20. Hartzell K, Avis K, Lozano D, Feig D. Obstructive sleep apnea and periodic limb movement disorder in a population of children with hypertension and/or nocturnal nondipping blood pressures. J Am Soc Hypertens. 2016;10(2): 101–107.
  21. Archbold KH, Vasquez MM, Goodwin JL, Quan SF. Effects of sleep patterns and obesity on increases in blood pressure in a 5-year period: report from the Tucson Children’s Assessment of Sleep Apnea Study. J Pediatr. 2012; 161(1):26–30
  22. Au CT, Ho CK, Wing YK, Lam HS, Li AM. Acute and chronic effects of sleep duration on blood pressure. Pediatrics. 2014;133(1). Available at: www. pediatrics. org/ cgi/ content/ full/ 133/ 1/ e64
  23. Александров А. А., Бубнова М. Г., Кисляк О. А. и др. Профилактика сердечно-сосудистых заболеваний в детском и подростковом возрасте. Российские рекомендации. Российский кардиологический журнал 2012; № 6 (Прил. 1): С. 1-40.
  24. Dionne J. et al. Pediatric Nephrology Hypertension in infancy: diagnosis, management and outcome //January 2012, Volume 27, Issue 1, pp 17–32.
  25. Hager A, Kanz S, Kaemmerer H,Schreiber C, Hess J. Coarctation Long-term Assessment (COALA):significance of arterial hypertension in a cohort of 404 patients up to 27 years after surgical repair of isolated coarctation of the aorta, even in the absence of restenosis and prosthetic material. J Thorac Cardiovasc Surg. 2007;134(3): 738–745/
  26. Di Salvo G, Castaldi B, Baldini L, Gala S, del Gaizo F, D’Andrea A, et al.Masked hypertension in young patients after successful aortic coarctation repair: impact on left ventricular geometry and function. J Hum Hypertens 2011; 25: 739–745
  27. Flynn J, Zhang Y, Solar-Yohay S, Shi V. Clinical and demographic characteristics of children with hypertension. Hypertension. 2012;60(4): 1047–1054
  28. Baracco R, Kapur G, Mattoo T, et al. Prediction of primary vs secondary hypertension in children. J Clin Hypertens (Greenwich). 2012;14(5): 316–321.
  29. Mattoo K. Evaluation and diagnosis of hypertension in infants between one month and one year of age // UpToDate This topic last updated: Jun 11, 2020
  30. O’Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al.,European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013; 31:1731–1768.
  31. Wu¨hl E, Witte K, Soergel M, Mehls O, Schaefer F, German Working Group on Pediatric Hypertension. Distribution of 24-h ambulatory blood pressure in children: normalized reference values and role of body dimensions. J Hypertens 2002; 20:1995–2007.
  32. Valent-Morić B, Zigman T, Zaja-Franulović O, Malenica M, Cuk M. The importance of ambulatory blood pressure monitoring in children and adolescents. Acta Clin Croat.2012;51(1):59–64.
  33. .Swartz SJ, Srivaths PR, Croix B, Feig DI. Cost-effectiveness of ambulatory blood pressure monitoring in the initial evaluation of hypertension in children. Pediatrics. 2008;122(6):1177–1181
  34. Kavey RE, Kveselis DA, Atallah N, Smith FC. White coat hypertension in childhood: evidence for end-organ effect. J Pediatr. 2007;150(5):491–497.
  35. Mitsnefes M, Flynn J, Cohn S, et al; CKiD Study Group. Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol.2010;21(1):137–144
  36. Lurbe E, Thijs L, Torro MI, Alvarez J, Staessen JA, Redon J. Sexual dimorphism in the transition from masked to sustained hypertension in healthy youths. Hypertension 2013; 62:410–414.
  37. Аверьянов С.Н., Амчеславский В.Г., Багаев В.Г., Тепаев Р.Ф. Определение скорости клубочковой фильтрации у детей: история и современные подходы. Педиатрическая фармакология. 2018; 15 (3): 218–223.doi: 10.15690/pf.v15i3.1901
  38. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Bohm M. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–2219. DOI: 10.1093/eurheartj/eht151
  39. Khoury PR, Mitsnefes M, Daniels SR, Kimball TR. Age-specific reference intervals for indexed left ventricular mass in children. J Am Soc Echocardiogr 2009; 22:709–714.
  40. Philip R. Khoury, Mark Mitsnefes, Stephen R. Daniels, Thomas R. Kimball, Age-Specific Reference Intervals for Indexed Left Ventricular Mass in Children,Journal of the American Society of Echocardiography, Volume 22, Issue 6, 2009,Pages 709-714
  41. Chinali M, Emma F, Esposito C, Rinelli G, Franceschini A, Doyon A, et al. Left ventricular mass indexing in infants, children, and adolescents: a simplified approach for the identification of left ventricular hypertrophy in clinical practice. J Pediatr 2016; 170:193–198.
  42. Moller N C, Grontvve A., Wedderkopp N/Cardiovascular disease risk factors and blood pressure response during in exercise during in health children and adolescents the European Youth Heart study J Appl Physiol 2010 ;109:1125-1132
  43. Lubrano R, Travasso E, Raggi C, Guido G, Masciangelo R, Elli M. Blood pressure load, proteinuria and renal function in prehypertensive children. Pediatr Nephrol 2009; 24:823–831.
  44. Agarwal A, Kapur G, Altinok D. Childhood posterior reversible encephalopathy syndrome: magnetic resonance imaging findings with emphasis on increased leptomeningeal FLAIR signal. Neuroradiol J 2015; 28:638–643.
  45. Hager A, Kanz S, Kaemmerer H,Schreiber C, Hess J. Coarctation Long-term Assessment (COALA):significance of arterial hypertension in a cohort of 404 patients up to 27 years after surgical repair of isolated coarctation of the aorta, even in the absence of restenosis and prosthetic material. J Thorac Cardiovasc Surg. 2007; 134(3):738–745/
  46. Di Salvo G, Castaldi B, Baldini L, Gala S, del Gaizo F, D’Andrea A, et al.Masked hypertension in young patients after successful aortic coarctation repair: impact on left ventricular geometry and function. J Hum Hypertens 2011; 25:739–745
  47. Giordano U, Cifra B, Giannico S, Turchetta A, Calzolari A. Mid-term results, and therapeutic management, for patients suffering hypertension after surgical repair of aortic coarctation. Cardiol Young 2009;19:451–455.
  48. Moltzer E, Mattace Raso FU, Karamermer Y, Boersma E, Webb GD, Simoons ML, et al. Comparison of candesartan versus metoprolol for treatment of systemic hypertension after repaired aortic coarctation. Am J Cardiol 2010; 105:217–222.
  49. Baracco R, Kapur G, Mattoo T, et al. Prediction of primary vs secondary hypertension in children. J Clin Hypertens (Greenwich). 2012;14(5):316–321.
  50. Elkins C, Fruh S, Jones L, Bydalek K. Clinical Practice Recommendations for Pediatric Dyslipidemia The Pediatr Health Care. Jul-Aug 2019;33(4):494-504. doi: 10.1016/j.pedhc.2019.02.009
  51. Zimmet P, Alberti KG, Kaufman F, Tajima N, et a. IDF Consensus Group. The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes. 2007 Oct;8(5):299-306.
  52. Torrance B., McGuire K.A., Lewanczuk R., McGavock J. Overweight, physical activity and high blood pressure in children: a review of the literature. Vasc Health Risk Manag 2007; 3(1): 139–149.
  53. Farpour-Lambert N.J., Aggoun Y., Marchand L.M., Martin X.E., Herrmann F.R.,Beghetti M. Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in pre-pubertal obese children. J Am Coll Cardiol 2009; 54(25): 2396–2406. DOI: 10.1016/j.jacc.2009.08.030
  54. Kelley G.A., Kelley K.S., Tran Z.V. The effects of exercise on resting blood pressure in children and adolescents: a meta-analysis of randomized controlled trials. Prev Cardiol 2003; 6(1): 8–16.
  55. Tompkins C.L., Moran K., Preedom S., Brock D.W. Physical activity-induced improvements in markers of insulin resistance in overweight and obese children and adolescents. Curr Diabetes Rev 2011; 7(3): 164-170.
  56. Damasceno M.M., de Araújo M.F., deFreitas R.W., de Almeida P.C., Zanetti M.L. The association between blood pressure in adolescents and the consumption of fruits, vegetables and fruit juice--an exploratory study. J Clin Nurs 2011; 20(11–12): 1553–1560.
  57. Moore L.L., Bradlee M.L., Singer M.R., Qureshi M.M., Buendia J.R., Daniels S.R. Dietary approaches to stop hypertension (DASH) eating pattern and risk of elevated blood pressure in adolescent girls. Br J Nutr 2012; 108(9): 1678–1685. DOI: 10.1017/S000711451100715X
  58. Saneei P., Hashemipour M., Kelishadi R., Rajaei S., Esmaillzadeh A. Effects of recommendations to follow the dietary approaches to stop hypertension (DASH) diet v. usual dietary advice on childhood metabolic syndrome: a randomized cross-over clinical trial. Br J Nutr 2013; 110(12): 2250–2259. DOI: 10.1017/S0007114513001724
  59. Yang Q., Zhang Z, Kuklina E.V. et al. Sodium intake and blood pressureamong US children and adolescents. Pediatrics 2012; 130(4): 611–619. DOI: 10.1542/peds.2011-3870
  60. Resnicow K., McMaster F., Bocian A., et al. Motivational interviewing and dietary counseling for obesity in primary care: an RCT. Pediatrics 2015; 135(4): 649–657. DOI: 10.1542/peds.2014-1880.
  61. Broccoli S., Davoli A.M., Bonvicini L., et al. Motivational interviewing to treat overweight children: 24-month follow-up of a randomized controlled trial. Pediatrics 2016; 137(1): e20151979. DOI: 10.1542/peds.2015-197930/wjc.v6.i5.234
  62. Dionne J.M., Harris K.C., Benoit G., FeberJ., Poirier L., Cloutier L. et al. Hypertension Canada's 2017 Guidelines for the Diagnosis, Assessment, Prevention, and Treatment of Pediatric Hypertension. CJC 2017; 33(5): 557-688. DOI.org/10.1016/j.cjca.2017.03.007
  63. Croxtall J.D. Valsartan: in children and adolescents with hypertension. Paediatr Drugs 2012; 14(3): 201–207. DOI: 10.2165/11208990-000000000-00000
  64. Wühl E., Trivelli A., Picca S., Litwin M., Peco-Antic A., Zurowska A. et al; ESCAPE Trial Group. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009; 361(17): 1639–1650. DOI: 10.1056/NEJMoa0902066.
  65. Wells T., Blumer J., Meyers K.E. Valsartan Pediatric Hypertension Study Group. Effectiveness and safety of valsartan in children aged 6 to 16 years with
  66. Webb N.J., Shahinfar S., Wells T.G., Massaad R., Gleim G.W., Santoro E.P. et al. Losartan and enalapril are comparable in hypertension. J Clin Hypertens (Greenwich) 2011; 13(5): 357–365. DOI: 10.1111/j.1751-7176.2011.00432reducing proteinuria in children. Kidney Int 2012; 82(7): 819–826. DOI: 10.1038/ki.2012.210
  67. Chu P.Y., Campbell M.J., Miller S.G., Hill K.D. Anti-hypertensive drugs in children and adolescents. World J Cardiol 2014; 6: 234-244. DOI: 10.43.
  68. Baker-Smith C.M., Benjamin D.K., Califf R.M. Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials. Clin Pharmacol Ther 2010; 87: 668-71. DOI: 10.1038/clpt.2009.231
  69. Schaefer F., Coppo R., Bagga A., Senguttuvan P., Schlosshauer R., Zhang Y. et al. Efficacy and safety of valsartan in hypertensive children 6 mon to 5 years of age. J Hypertens 2013; 31(5): 993–1000. DOI: 10.1097/HJH.0b013e32835f5721
  70. Schaefer F., Litwin M., Zachwieja J., Zurowska A., Turi S., Grosso A. et al. Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study. J Hypertens 2011; 29(12): 2484–2490. DOI: 10.1097/HJH.0b013e32834c625c
  71. Trachtman H., Hainer J.W., Sugg J. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens (Greenwich) 2008; 10: 743-50. DOI: 10.1111/j.1751-7176.2008.00022
  72. Hazan L., Hernández Rodriguez O.A., Bhorat A.E., Miyazaki K., Tao B., Heyrman R. et al. Assessment of Efficacy an Olmesartan in Pediatric Hypertension Study Group. A doubleblind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension 2010; 55(6): 1323–1330. DOI: 10.1161/HYPERTENSIONAHA.109.147702
  73. Simonett G.D., von Vigier R.O., Konrad M., Rizzi M., Fossali E., Bianchetti M.G. Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. Pediatr Nephrol 2006; 21(10): 1480–1482.
  74. Flynn J.T. Efficacy and safety of prolonged amlodipine treatment in hypertensive children. Pediatr Nephrol 2005; 20(5):631–635.
  75. Trachtman H., Frank R., Mahan J.D., Portman R., Restaino I., Matoo T.K. et al. Clinical trial of extended release felodipine in pediatric essential hypertension. Pediatr Nephrol 2003; 18: 548-553. DOI: 10.1007/s00467-003-1134-0
  76. Sica D.A., Carter B., Cushman W., Hamm L. Thiazide and loop diuretics. J Clin Hypertens (Greenwich) 2011; 13: 639-643 DOI: 10.1111/j.1751-7176.2011.00512
  77. Karnes J.H., Cooper-DeHoff R.M. Antihypertensive medications:benefits of blood pressure lowering and hazards of metabolic effects. Expert Rev Cardiovasc Ther 2009; 7: 689-702. DOI: 10.1586/erc.09.31
  78. Li J.S., Flynn J.T., Portman R., Davis I., Ogawa M., Shi H. et al. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. J Pediatr 2010; 157(2): 282–287. DOI: 10.1016/j.jpeds.2010.02.042
  79. Meyers R.S., Siu A. Pharmacotherapy review of chronic pediatric hypertension. Clin Ther 2011; 33: 1331-1356. DOI: 10.1016/j.clinthera.2011.09.003
  80. Batisky D.L., Sorof J.M., Sugg J., Llewellyn M., Klibaner M., Hainer J.W., et al. Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. J Pediatr 2007; 150(2): 134–139. DOI: 10.1016/ j.jpeds.2006.09.034
  81. Poirier L., Lacourcière Y. The evolving role of β-adrenergic receptor blockers in managing hypertension. Can J Cardiol 2012; 28: 334-340. DOI: 10.1016/j.cjca.2012.04.001
  82. Poirier L., Tobe S.W. Contemporary use of beta-blocker: clinical relevance of subclassification. Can J Cardiol 2014; 30: S9-15. DOI: 10.1016/j.cjca.2013.12.001
  83. Daugherty S.L., Powers J.D., Magid D.J., Tavel H.M., Masoudi F.A., Margolis K.L. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125: 1635–1642. DOI: 10.1161/CIRCULATIONAHA.111.068064
  84. Narayan H., Webb D.J. New evidence supporting the use of mineralocorticoid receptor blockers in drug-resistant hypertension. Curr Hypertens Rep 2016; 18(5): 34. DOI:10.1007/s11906-016-0643-8
  85. Williams B., MacDonald T.M., Morant S., Webb D., Sever P., McInnes G. et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment or drug-resistant hypertension(PATHWAY-2): a randomised, doubleblind, crossover trial. Lancet 2015; 386(10008): 2059–2068. DOI: 10.1016/S0140-6736(15)00257-3
  86. White W.B., Turner J.R., Sica D.A. Detection, evaluation, and treatment of severe and resistant hyperteion: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., 2013. J Am Soc Hypertens 2014; 8(10): 743–757/ DOI: 10.1016/j.jash.2014.06.005
  87. .Gartenmann A.C., Fossali E., von Vigier R.O., Simonetti G., Schmidtko J., Edefonti A., et al. Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood. Kidney Int 2003; 64(4): 1450–1454.

88. Пономаренко Г.Н., Ковлен Д.В. Физическая и реабилитационная медицина. Клинические рекомендации, основанные на доказательствах. / Под ред. А.Н.Разумова. М.: Наука, 2020.

89. Разумов А.Н. Санаторно-курортное лечение: национальное руководство / под ред. А. Н. Разумова, В. И. Стародубова, Г. Н. Пономаренко. Москва: ГЭОТАР-Медиа, 2021. 752с.

90. Шлык Н. И. Лечебная физическая культура при заболеваниях сердечно-сосудистой системы: учебно-методическое пособие. Ижевск: «Удмуртский университет», 2014. 115 с.

91. Епифанов В.А. Лечебная физическая культура и массаж: учебник. М.: ГЭОТАР-Медиа, 2013. 528 с.

92. Каладзе Н.Н., Ревенко Н.А., Мельцева Е.М., Дусалеева Т.М. Влияние электросонтерапии на динамику биоритмологической активности гормонов адаптации у детей с артериальной гипертензией в процессе санаторно-курортного лечения // Вестник восстановительной медицины, 2017, № 3. С.46-50.

93. Казаков В.Ф.,Макарова И.Н., Серяков В.В. и др. Реабилитация при заболеваниях сердечно-сосудистой системы Под ред. И.Н. Макаровой. М.: ГЭОТАР-Медиа, 2010. 304 с.

94. Ревенко Н. А., Каладзе Н. Н., Алешина О. К. Комбинированная санаторно-курортная реабилитация детей с артериальной гипертензией и метаболическими нарушениями. Российский кардиологический журнал. 2021, 26(S6).

95. Хан М.А., Погонченкова И.В., Вахова Е.Л., Рассулова М.А., Лян Н.А., Бокова И.А. Сухие углекислые ванны в медицинской реабилитации детей //Доктор.Ру. 2018. Т. 149. № 5. С. 51-56

96. Давыдова О.Б., Тупицина Ю.Ю., Анисимкина А.Н. Лечебное действие хлоридных натриевых ванн. //Росс. мед. журнал. 2002.№2.с. 36.

97. Абусева Г.Р. и др. Физическая и реабилитационная медицина: национальное руководство. Краткое издание. 2019. C. 512.

98. Хан М. А. и др. Физическая и реабилитационная медицина в педиатрии //М.: ГЭОТАР-Медиа. 2018. C. 408.

99. Беспалова И.Д., Медянцев Ю.А., Калюжин В.В., Мурашев Б.Ю., Осихов И.А. Качество жизни больных гипертонической болезнью с метаболическим синдромом.// Артериальная гипертензия. 2012. 18(4). с. 304-309.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы:
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*